Methods of treating neurological conditions with hematopoeitic growth factors
The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.
1. A method of treating Parkinson's disease in a mammal, consisting of administering to the mammal in need thereof, a hematopoietic factor selected from the group consisting of mammalian granulocyte-colony stimulating factor (G-CSF), human G-CSF, a protein having at least 90% homology to SEQ ID NO:37, a protein having at least 90% homology to SEQ ID NO:38, a protein having at least 90% homology to SEQ ID NO:39, PEG-modified G-CSF or a combination thereof in an amount sufficient to treat the Parkinson's disease; and
optionally one or more of trihexyphenidyl, selegiline, L-DOPA, and pergolide; and
optionally a pharmaceutical acceptable carrier or excipient.
2. The method of claim 1 , wherein the hematopoietic factor is a human factor or derived from a human factor.
3. The method of claim 1 , wherein the mammal is human.
4. The method of claim 1 , wherein the hematopoietic factor is administered by one or more modes of administration selected from the group consisting of direct intracerebral injection, intravenously, intraarterially, orally, subcutaneously, and via implanted mini-pump.
5. The method of claim 1 , wherein the hematopoietic factor is administered daily.
6. The method of claim 1 , wherein mammalian G-CSF is administered.
7. The method of claim 1 , wherein human G-CSF is administered.
8. The method of claim 1 , wherein a protein having at least 90% homology to SEQ ID NO:37 is administered.
9. The method of claim 1 , wherein a protein having at least 90% homology to SEQ ID NO:38 is administered.
10. The method of claim 1 , wherein a protein having at least 90% homology to SEQ ID NO:39 is administered.
11. The method of claim 1 , wherein a combination of hematopoietic factors is administered.
12. The method of claim 1 , wherein one or more of trihexyphenidyl, selegiline, L-DOPA, and pergolide are administered.
13. A method of treating Parkinson's disease in a mammal, comprising administering to the mammal in need thereof, a hematopoietic factor selected from the group consisting of mammalian granulocyte-colony stimulating factor (G-CSF), human G-CSF, a protein having at least 90% homology to SEQ ID NO:37, a protein having at least 90% homology to SEQ ID NO:38, a protein having at least 90% homology to SEQ ID NO:39, PEG-modified G-CSF or a combination thereof in a daily dose of from 20 to 250 μg/kg to treat the Parkinson's disease.
14. The method of claim 13 , wherein the dose is from 60 to 250 μg/kg.
15. The method of claim 13 , wherein the hematopoietic factor is a human factor or derived from a human factor.
16. The method of claim 13 , wherein the mammal is human.
17. The method of claim 13 , wherein the hematopoietic factor is administered by one or more modes of administration selected from the group consisting of direct intracerebral injection, intravenously, intraarterially, orally, subcutaneously, and via implanted mini-pump.
18. The method of claim 13 , wherein mammalian G-CSF is administered.
19. The method of claim 13 , wherein human G-CSF is administered.
20. The method of claim 13 , wherein a protein having at least 90% homology to SEQ ID NO:37 is administered.
21. The method of claim 13 , wherein a protein having at least 90% homology to SEQ ID NO:38 is administered.
22. The method of claim 13 , wherein a protein having at least 90% homology to SEQ ID NO:39 is administered.
23. The method of claim 13 , wherein a combination of hematopoietic factors is administered.